Teladoc (NYSE:TDOC) hit a new 52-week high and low during mid-day trading on Thursday . The company traded as low as $50.70 and last traded at $50.60, with a volume of 673212 shares changing hands. The stock had previously closed at $49.85.
A number of equities research analysts have recently issued reports on TDOC shares. ValuEngine raised shares of Teladoc from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $35.00 price objective (up previously from $31.00) on shares of Teladoc in a research note on Tuesday, February 27th. Deutsche Bank increased their price target on shares of Teladoc to $45.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Canaccord Genuity increased their price target on shares of Teladoc from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, SunTrust Banks increased their price target on shares of Teladoc to $48.00 and gave the company a “positive” rating in a research report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $42.67.
Get Teladoc alerts:
The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -30.67 and a beta of 0.35. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.15 and a current ratio of 4.15.
Teladoc (NYSE:TDOC) last posted its earnings results on Tuesday, May 1st. The health services provider reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.04. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. The firm had revenue of $89.64 million during the quarter, compared to analysts’ expectations of $86.77 million. During the same period last year, the company posted ($0.30) EPS. The company’s quarterly revenue was up 109.0% compared to the same quarter last year. analysts anticipate that Teladoc will post -1.37 earnings per share for the current year.
In other news, CFO Mark Hirschhorn sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $39.60, for a total value of $3,960,000.00. Following the completion of the sale, the chief financial officer now directly owns 98,960 shares of the company’s stock, valued at approximately $3,918,816. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jason N. Gorevic sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $48.93, for a total transaction of $1,223,250.00. Following the completion of the sale, the chief executive officer now directly owns 636,184 shares of the company’s stock, valued at $31,128,483.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 483,954 shares of company stock valued at $19,960,682. Corporate insiders own 3.95% of the company’s stock.
Large investors have recently bought and sold shares of the company. Allianz Asset Management GmbH increased its stake in shares of Teladoc by 25.8% in the 1st quarter. Allianz Asset Management GmbH now owns 34,745 shares of the health services provider’s stock worth $1,401,000 after acquiring an additional 7,116 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Teladoc by 3.4% in the 1st quarter. Principal Financial Group Inc. now owns 118,266 shares of the health services provider’s stock worth $4,767,000 after acquiring an additional 3,839 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of Teladoc in the 1st quarter worth about $238,000. Levin Capital Strategies L.P. bought a new position in shares of Teladoc in the 1st quarter worth about $403,000. Finally, Xact Kapitalforvaltning AB increased its stake in shares of Teladoc by 46.3% in the 1st quarter. Xact Kapitalforvaltning AB now owns 8,530 shares of the health services provider’s stock worth $344,000 after acquiring an additional 2,700 shares in the last quarter.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.